TROPION-Lung15: a randomized phase III study of osimertinib combined with datopotamab deruxtecan (Dato-DXd) or Dato-DXd alone versus platinum-doublet chemotherapy in patients with <i>EGFR</i>-mutated advanced non-small cell lung cancer and whose disease has progressed on prior osimertinib.

ABSTRACT:

Background

Osimertinib is the preferred treatment for patients with EGFR-mutated advanced non-small cell lung cancer (NSCLC) in several settings; however, disease progression is common, and treatment options after progression are limited. Datopotamab deruxtecan (Dato-DXd), an antibody-drug conjugate comprising a humanized anti-trophoblast cell-surface antigen 2 (TROP 2) monoclonal antibody conjugated to a potent topoisomerase I inhibitor via a plasma-stable linker, has demonstrated efficacy in advanced NSCLC, including previously treated EGFR-mutated advanced NSCLC. Combining osimertinib and Dato-DXd may overcome heterogeneous osimertinib resistance mechanisms and limit tumor progression.

Objectives

TROPION-Lung15 is an ongoing, phase III, open-label, sponsor-b

SUBMITTER: Tan DS 

PROVIDER: S-EPMC12743830 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature